| P2093 | author name string | Roberto Zatz | |
| | Clarice Kazue Fujihara | |
| | Irene Lourdes Noronha | |
| P2860 | cites work | Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion | Q41698111 |
| | Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis | Q42048902 |
| | Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts | Q42555924 |
| | Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension | Q43420596 |
| | Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure | Q43623103 |
| | Mycophenolate mofetil impairs healing of left-sided colon anastomoses | Q43629279 |
| | Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition | Q43635169 |
| | Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice | Q43658790 |
| | Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis | Q43688347 |
| | Effect of mycophenolate mofetil on nitric oxide production and inducible nitric oxide synthase gene expression during renal ischaemia-reperfusion injury | Q43690490 |
| | In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells | Q43695984 |
| | The safety and efficacy of MMF in lupus nephritis: a pilot study | Q43777987 |
| | Effect of mycophenolate mofetil on the progression of adriamycin nephropathy | Q43810613 |
| | Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats | Q43852739 |
| | Mycophenolate mofetil treatment for primary glomerular diseases | Q43889676 |
| | Mycophenolate mofetil aggravates postischemic acute renal failure in rats | Q43962989 |
| | Advanced glycosylation end products in patients with diabetic nephropathy | Q44031994 |
| | Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease | Q44663778 |
| | Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. | Q53920423 |
| | Use of mycophenolate mofetil in resistant membranous nephropathy. | Q54042560 |
| | Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. | Q54127944 |
| | A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1 | Q57704207 |
| | Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 |
| | Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice | Q28344894 |
| | Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass | Q28360314 |
| | Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat | Q28360398 |
| | The effect of mycophenolate mofetil and polyphenolic bioflavonoids on renal ischemia reperfusion injury and repair | Q28371082 |
| | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 |
| | Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. | Q33177527 |
| | Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway | Q33903180 |
| | The use of mycophenolate mofetil in transplant recipients | Q33957200 |
| | Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells | Q34150690 |
| | Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage | Q35604343 |
| | Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor | Q36925657 |
| | Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension | Q36994591 |
| | Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor | Q37371633 |
| | Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil | Q38324351 |
| | Nephron adaptation to renal injury or ablation | Q39829024 |
| | Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis | Q39912818 |
| | Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines | Q40933631 |
| | Role of dietary protein and blood pressure in the progression of renal disease | Q41066756 |
| P433 | issue | 6 | |
| P304 | page(s) | F1167-75 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | American Journal of Physiology - Renal Physiology | Q2610177 |
| P1476 | title | Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies | |
| P478 | volume | 283 | |